Skip to main content

Cortical and lesion remyelination in relapsing-remitting multiple sclerosis patients from the Opicinumab (Anti-LINGO-1) phase II clinical trial (Synergy). A validation study of the T1-weighted and T2-weighted ratio approach (RAPOR)

VHIR Annual Report 2021